2m 2m 2m 2m 2m 2m 2m
Alnylam Pharma (ALNY)
NASDAQ
$239.62+$0.06 (+0.02%)
Price as of Sep 18, 2026 7:30 PM EDT- $32.9BMarket Cap
- -45.70%1-Year Change
- BiotechnologyIndustry
Alnylam Pharma (ALNY)
$239.62+$0.06 (+0.02%)
ALNY | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $239.56 | ||
Change | +$6.15 (+2.57%) | ||
Open | $246.41 | ||
High | $246.49 | ||
Low | $238.51 | ||
Previous Close | $245.51 | ||
Volume | 2,756,179 | ||
30-Day Average Volume | 1,651,782 | ||
1-Week Change | -0.81% | ||
1-Month Change | 9.31% | ||
1-Year Change | -45.70% | ||
3-Year Change | 32.72% | ||
5-Year Change | 28.98% | ||
Fundamentals | |||
Shares Outstanding | 133.8M | ||
Total Assets | $5.6B | ||
Market Cap | $32.9B | ||
Enterprise Value | $32.2B | ||
Period: QTR TTM FY | |||
Revenue | $1.2B | ||
Net Income | $164.5M | ||
Free Cash Flow | $292.0M | ||
EBIT | $177.8M | ||
EBITDA | $191.7M | ||
Net Working Capital | $3.1B | ||
EPS | $1.21 | ||
Enterprise Value/EBITDA | 168 | ||
Enterprise Value/Revenue | 27 | ||
P/B | 24 | ||
P/E | 203 | ||
PEG | -10 | ||
Price/Free Cash Flow | 112 | ||
Price/Operating Cash Flow | 101 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue